Latest News & Updates
NEW THIS YEAR — Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny
February 3, 2027 • 10am–4pm
Learn MoreGet a Sneak Peek of the 2027 Agenda!
View AgendaPreparing for the Next Era of Controlled Substances Regulation, Enforcement, and Compliance
The controlled substances landscape is entering another period of significant regulatory and enforcement change. Legal, compliance, and regulatory leaders must navigate evolving DEA and DOJ priorities, heightened scrutiny around diversion and suspicious-order monitoring, changing telemedicine requirements, quota and supply pressures, and growing enforcement risk across manufacturers, distributors, pharmacies, healthcare providers, and prescribers.
At the same time, AI-driven compliance tools, digital commerce, emerging substances, and shifting federal and state policy are creating new operational and legal challenges across the market.
Join industry leaders, regulators, legal practitioners, and compliance executives at the 8th Annual Summit on Controlled Substances: Regulation, Litigation, and Enforcement to benchmark compliance strategies, understand where enforcement is heading, and prepare for the next wave of controlled substances risk.
Conference Co-Chairs
Jolie Apicella
Partner
Wiggin and Dana, LLP
Former Chief, Civil Health Care Fraud
United States Attorney’s Office
Gus Eyler
Partner
Gibson, Dunn & Crutcher LLP
Former Director, Consumer Protection Branch, Civil Division
U.S. Department of Justice
Cori L. Rizman
Vice President of DEA Compliance
Ascent Pharmaceuticals, Inc.
Former Diversion Group Supervisor
Drug Enforcement Administration
Hear Directly from Government Officials
Colin M. McDonald
Assistant Attorney General, National Fraud Enforcement Division
U.S. Department of Justice
Debbie Seguin
Deputy Director, Office of National Drug Control Policy (ONDCP), Executive Office of the President
The White House
Dominic Chiapperino, Ph.D.
Director, Controlled Substances Staff
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Matthew Feeley
Chief, USAO SDFL Civil Division
U.S. Department of Justice
Featured Speakers
Laura Bray
Founder
Angels for Change
Joseph Shepherd
Global Senior Director, Controlled Substance Leader
Johnson & Johnson Innovative Medicine
Joseph Nguyen
Director, Controlled Substances & Pharmacy Compliance;
Interim Director, Compliance Investigations
Office of Institutional Compliance & Audit Services
UT Southwestern Medical Center
Rob Park
Senior Vice President and Associate General Counsel
McKesson
Krista Tongring
President, DEA Regulatory Compliance Practice
Guidepost Solutions
Former Acting Section Chief, Office of Compliance, Policy Administration Section; Former Senior Attorney, Diversion and Regulatory Litigation Section, Drug Enforcement Administration
Eric Triana
Chief Compliance & Legal Officer
Talkiatry
Former Deputy Assistant Administrator, Office of Diversion Operations, Diversion Control Division, Drug Enforcement Administration
Why You Need to Attend
As enforcement priorities evolve and regulatory expectations become increasingly complex, organizations must proactively identify risk, strengthen compliance programs, and prepare for the next generation of regulatory and enforcement challenges.
Anticipate the regulatory, enforcement, and policy developments shaping the future of controlled substances oversight
Prepare for the next phase of telemedicine prescribing under DEA’s Special Registration framework
Navigate evolving risks associated with marijuana rescheduling, hemp-derived cannabinoids, psychedelics, kratom, and other emerging substances
Strengthen diversion prevention, prescription validity, and monitoring programs in an era of heightened enforcement
Leverage AI, data analytics, ARCOS intelligence, and advanced monitoring tools to identify and mitigate compliance risk
Manage healthcare fraud, dispensing liability, supply chain, and quota-related challenges through practical compliance strategies
Stay ahead of evolving federal and state enforcement trends to reduce legal, regulatory, and operational exposure
Our Audience at a Glance
Pharmaceutical/ Biotechnology Research Organizations
General Counsel
Officers, Executives, Vice Presidents, Directors, and Senior Managers of:
- Controlled Substances
- Pharmacy Compliance
- Diversion Control
- DEA Compliance
- Regulatory & Compliance Operations
- Quality Compliance
- Ethics
- Abuse & Risk Assessment
Healthcare
General Counsel
Officers, Executives, Vice Presidents, Directors, and Senior Managers of:
- Pharmacy
- Diversion Control
- Operations
- Procurement
- Distribution
- Regulatory Affairs & Compliance
- Quality Management
- DEA Compliance
Retail Manufacturers and Pharmacies
Pharmacists
Officers, Executives, Vice Presidents, Directors, and Senior Managers of:
- Controlled Substances
- Operations
- Regulatory Affairs & Compliance
- Investigations
- Professional Practice
- DEA Compliance
Other Industries including:
- Federal & State Level Government Officials
- Environmental Services
- Logistics Distribution
Outside Counsel/Consultants
New This Year
Life Sciences Enforcement Operations LAB: Building the First 72-Hour Response to FDA, DEA, DOJ and State Scrutiny
This limited-seat, scenario-driven LAB puts legal, compliance, quality, regulatory and investigations leaders inside an escalating life sciences enforcement matter and challenges them to manage the critical first 72 hours. Work through inspections, subpoenas, regulator interactions, employee interviews, document preservation, internal escalation and operational risk while building a practical response playbook you can take back to the office.
Learn More
Featured Article
Companies Confront New Challenges in Regulation of Controlled Substances
Learn more about how manufacturers and distributors of controlled substances can ensure they have strong compliance systems and avoid government enforcement actions.
Read NowWebinar Recording
From Red Flags to FCA Risk: A One Hour Briefing for Controlled Substances Stakeholders
Watch Now
Testimonials
“Our partnership with ACI has been a valuable part of Guidepost Solutions’ business development efforts, and that value flows through to our clients. ACI’s conferences are consistently well-run and informative, giving our team the chance to both attend and speak alongside other thought leaders. Those exchanges of ideas push our thinking forward and help us grow as practitioners. We’re proud to sponsor ACI and to be part of a community that takes this work seriously.”—Guidepost Solutions
“This was one of the better controlled substance conferences since many of the other ones repeat the same topics. This was progressive and relevant.”—Ascent Pharmaceuticals
“This conference was spot on with the issues we are facing everyday.”—Novartis Institutes for Biomedical Research
“It was great to hear from current and former industry leaders and experts from DEA, US AG offices, FDA, etc. Hearing about the current events and upcoming trends/expectations was valuable.”—Kroger Health
“As the Director of Compliance for IPC, I was extremely pleased with last year’s speakers and the insight they provided into the latest controlled substance regulations.”—Independent Pharmacy Cooperative
Sponsors & Partners
Associate Sponsors
Lanyard Sponsor
Sponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Ken Glass
Senior Business Development Manager
Phone: 416-998-8883
Email: [email protected]
